Table 5. Characteristics of clinical trials studying baricitinib in patients with COVID-19.
Clinical trial ID | Status | Study Results | Conditions | Interventions | Locations |
NCT04321993 | Recruiting | No results available | COVID-19 | Drug: Lopinavir/ritonavir drug: Hydroxychloroquine sulfate drug: Baricitinib | Canada |
NCT04401579 | Recruiting | No results available | COVID-19 | Other: Placebo drug: Remdesivir drug: Baricitinib | USA |